Skip to main content

Advertisement

Table 1 Sample characteristics

From: Impact of adult growth hormone deficiency on daily functioning and well-being

Sample size Germany United Kingdom United States Total
(n = 14) (n = 12) (n = 13) (n = 39)
Gender; n (%)     
  Female 8 (57) 6 (50) 9 (69) 23 (59)
  Male 6 (43) 6 (50) 4 (31) 16 (41)
Ethnicity; n (%)     
  Caucasian/White 3 (21) 11 (92) 9 (69) 23 (59)
  Latino 0 (0) 0 (0) 3 (23) 3 (8)
  Asian 1 (7) 1 (8) 0 (0) 2 (5)
  Mixed 1 (7) 0 (0) 0 (0) 1 (3)
  Other 0 (0) 0 (0) 1 (8) 1 (3)
  Decline to report 9 (64) 0 (0) 0 (0) 9 (23)
Marital Status; n (%)     
  Married 8 (57) 7 (58) 7 (54) 22 (56)
  Single 2 (14) 3 (25) 4 (31) 9 (23)
  Partnered 2 (14) 1 (8) 2 (15) 5 (13)
  Divorced 2 (14) 0 (0) 0 (0) 2 (5)
  Widowed 0 (0) 1 (8) 0 (0) 1 (3)
Age; mean (range) 53.1 52.5 46.4 50.7
(22–77) (23–82) (22–71) (22–82)
Highest level of education; n (%)     
  High school/technical (or lower) 5 (36) 4 (33) 5 (38) 14 (36)
  College degree 7 (50) 3 (25) 6 (46) 16 (41)
  Graduate (or higher) 2 (14) 5 (42) 2 (15) 9 (23)
Employment status; n (%)     
  Not working for pay 7 (50) 5 (42) 4 (31) 16 (41)
  Full time for pay 4 (29) 7 (58) 5 (38) 16 (41)
  Part time for pay 2 (14) 0 (0) 4 (31) 6 (15)
  Student 1 (7) 0 (0) 0 (0) 1 (3)
Age (years) at GHD diagnosis; mean (range) 42.0 38.9 38.0 39.7
(8–63) (4–71) (10–61) (4–71)
Cause of AGHD; n (%)     
  Pituitary disease/tumor 12 (86) 8 (67) 4 (31) 24 (62)
  Head trauma 0 (0) 0 (0) 2 (15) 2 (5)
  Short stature 1 (7) 0 (0) 1 (8) 2 (5)
  Hypopituitarism 0 (0) 1 (8) 1 (8) 2 (5)
  Acromegaly; removal of pituitary gland 0 (0) 1 (8) 1 (8) 2 (5)
  Brain tumor 0 (0) 1 (8) 0 (0) 1 (3)
  Unknown 1 (7) 1 (8) 4 (31) 6 (15)
Currently on GH treatment; n (%)     
  Yes 13 (93) 12 (100) 9 (69) 34 (87)
  No 1 (7) 0 (0) 4 (31) 5 (13)
Age (years) first took GH treatment; mean (range) 45.7a 44.3 38.9b 43.0c
(8–63) (5–71) (11–61) (5–71)
Number other prescription meds currently taking; mean (range) 5.0a 3.9 3.4 4.1
(1–15) (1–7) (0–7) (0–15)
Total AGHDA d score per country; mean (range) e 7.9 9.8 11.5 9.7
(0–20) (0–22) (0–23) (0–23)
Number co-morbid conditions; mean (range) 3.4 2.2 2.6 2.8
(1–7) (0–4) (0–8) (0–8)
  1. aOne blank response.
  2. bOne participant had never been on medication.
  3. cTwo missing responses, n = 37.
  4. dAGHDA: Quality of Life in Adult Growth Hormone Deficiency Assessment.
  5. eScored 1 point for positive response, possible range 0–25.